AstraZeneca Pharmaceuticals LP
2370 articles with AstraZeneca Pharmaceuticals LP
-
Although the COVID-19 pandemic is waning in the U.S., there is still plenty of research and news about the disease. Here’s a look.
-
CALQUENCE Demonstrated Fewer Incidences of Atrial Fibrillation Versus Ibrutinib in Previously Treated Patients With Chronic Lymphocytic Leukemia and Sustained Patient Benefit at Four Years in the Front-line Setting
6/7/2021
ELEVATE-RR head-to-head trial in previously treated patients showed less cardiovascular toxicity and fewer discontinuations due to adverse events for CALQUENCE versus ibrutinib
-
After three years, 85.9% of patients treated post-surgically with Lynparza were free of invasive breast cancer and second cancers compared to 77.1% of the placebo group.
-
With the 2021 American Society of Clinical Oncology Annual Meeting now in high gear, there is plenty of news. Here’s a look at just some of the most recent stories.
-
Akoya and AstraZeneca to Collaborate on Spatial Biology Approach to Profiling Tumor-Immune Biology
6/4/2021
Partnership aims to leverage spatial biology data, generated on Akoya’s Phenoptics™ platform, to inform and guide drug development programs
-
LYNPARZA® (olaparib) Reduced the Risk of Invasive Disease Recurrence or Death by 42% Versus Placebo in Adjuvant Treatment of Patients With Germline BRCA Mutations and High-Risk HER2-Negative Early Breast Cancer in Phase 3 OlympiA Trial
6/3/2021
First Medicine Specifically Targeting BRCA Mutations to Demonstrate Statistically Significant Improvement in Invasive Disease-Free Survival in Adjuvant Setting Following Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy
-
Statement from the Council of Chief Medical Officers of Health (CCMOH): Interchangeability of Authorized COVID-19 Vaccines
6/2/2021
Canada's approach to vaccination has enabled individuals in Canada to protect themselves, their families and communities against severe COVID-19 outcomes and reduce the risk of transmission of the virus.
-
Proteros Enters Into Oncology Collaboration and License Agreement With AstraZeneca
6/2/2021
Proteros biostructures GmbH announced that it has signed an agreement with AstraZeneca to jointly discover and develop novel small molecules for the potential treatment of various types of cancer.
-
As the Pfizer-BioNTech COVID-19 vaccine is being evaluated by the U.S. FDA and the Moderna vaccine is soon to follow, here’s a look at several of the top COVID-19 vaccine candidates and where they stand as of today.
-
The UK’s Competition and Markets Authority (CMA) will determine if the deal is anti-competitive.
-
Silence Therapeutics Receives Remaining $40 Million from AstraZeneca as Part of Upfront Investment for Ongoing siRNA Collaboration
5/25/2021
Silence Therapeutics Receives Remaining $40 Million from AstraZeneca as Part of Upfront Investment for Ongoing siRNA Collaboration
-
Clinical Catch-Up: May 17-21
5/24/2021
It was another busy week for clinical trial announcement. Here’s a look. -
The House Select Subcommittee on the Coronavirus Crisis questioned executives from Emergent BioSolutions as part of a congressional probe.
-
Companies have already begun their announcements of new clinical studies for various treatment settings in preparation for ASCO 2021.
-
New FASENRA® Data From the MELTEMI Extension Trial Confirm Long-Term Safety and Efficacy in Severe Eosinophilic Asthma for up to Five Years
5/19/2021
Results from a new integrated analysis including data from the MELTEMI Phase III open-label extension trial showed FASENRA® was well-tolerated for up to five years, with a long-term safety profile consistent with previous Phase III trials in adult patients with severe asthma.
-
FDA says it is possible booster shots would be necessary for fully vaccinated individuals within a year even though vaccines are highly effective at COVID-19 prevention.
-
"MarketWatch" Features Halberd Corporation With Prominent Pharmaceutical Companies on New Treatments for COVID-19
5/19/2021
Halberd Corporation was featured in a recent MarketWatch article, "New Approaches to Covid-19 Treatment Enter the Picture," along with six other notable biotechnology companies.
-
Sanofi and GSK expect to launch a global pivotal Phase III trial of its COVID-19 vaccine in the coming week.
-
New Tezepelumab Data Continue To Strengthen Profile For A Broad Population Of Severe Asthma Patients
5/13/2021
NAVIGATOR Data Published in New England Journal of Medicine, and Latest Data from Tezepelumab Clinical Program Presented at ATS 2021 International Conference
-
Former AstraZeneca Personalized Healthcare Strategy Leader Named Senior Vice President of Companion Diagnostics at DiaCarta
5/13/2021
DiaCarta Inc., a precision molecular diagnostics company and leading developer of novel oncology tests using liquid biopsy, announced the appointment of Hongjun "Harry" Yang, Ph.D., former Executive Personalized Healthcare Strategy Leader at AstraZeneca, as Senior Vice President of Companion Diagnostics at DiaCarta.